26 patents
Page 2 of 2
Utility
Compositions and Methods for Treating Ocular Diseases
8 Apr 20
Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like.
Kevin Peters, Robert Shalwitz
Filed: 2 Sep 19
Utility
Humanized monoclonal antibodies that target protein tyrosine phosphatase-beta (HPTP-β/VE-PTP)
30 Mar 20
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Kevin Peters, Michael Allen Flynn
Filed: 4 Nov 18
Utility
Multispecific Antibodies That Target HPTP-B (Ve-ptp) and Vegf
25 Mar 20
The disclosure provides compositions comprising multi-specific compounds, including a compound that targets a phosphatase and a receptor tyrosine kinase agonist.
Kevin Peters
Filed: 22 Sep 19
Utility
Methods of treating ocular conditions by administering humanized monoclonal antibodies that target VE-PTP (HPTP-beta)
23 Mar 20
The disclosure provides compositions and methods for the treatment of ocular conditions associated with angiogenesis comprising administering an antibody that targets a tyrosine phosphatase inhibitor in a subject.
Kevin Peters, Michael Allen Flynn
Filed: 4 Nov 18
Utility
Compositions and Methods for Treating Ocular Edema, Neovascularization and Related Diseases
8 Jan 20
Disclosed are methods for the treatment of diseases or conditions of the eye, especially retinopathies, ocular edema and ocular neovascularization.
Kevin Gene PETERS, Robert Shalwitz
Filed: 15 Jul 19
Utility
Human protein tyrosine phosphatase inhibitors and methods of use
4 Nov 19
The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-β) inhibitors thereby regulating angiogenesis.
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Filed: 14 Sep 17